Reported 3 days ago
Bank of America Securities has reaffirmed its Buy rating on Vaxcyte, Inc. (NASDAQ:PCVX), setting a price target of $134.00. The company recently entered an agreement with Thermo Fisher Scientific to enhance U.S. manufacturing of its broad-spectrum pneumococcal conjugate vaccines, marking a significant long-term commitment estimated at up to $1 billion. Vaxcyte is focused on innovative vaccine development to combat bacterial infectious diseases.
Source: YAHOO